Alzinova AB (publ)
Annual Report 2024

alzinova

We will make it possible for Alzheimer's patients to live an *independent and active life.*

Table of Contents

About Alzinova

Financials

The terms "Company" or "Alzinova" refer to Alzinova AB (publ) with organization number 556861-8168. The information in the annual report regarding markets, competition and future growth represents Alzinova's assessment, mainly based on material internally within the Company and from external sources. The Swedish krona (SEK) is the currency used consistently and unless otherwise stated, figures in brackets refer to operations in 2023. Some figures have been rounded, which may mean that tables and calculations do not always add up exactly. The formal annual report can be found on pages 25-42.

Please note that this is an English translation of the Annual Report written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova

Alzinova AB is a Swedish biopharmaceutical company that specializes in the treatment of Alzheimer's disease.

The Company's patented AβCC peptide technology™ enables the development of disease-modifying therapies with the potential to selectively neutralize neurotoxic Amyloid β (Aβ) oligomers, which play a central role in the onset and progression of the disease. With this technology, Alzinova can develop precise and effective treatments, while minimizing the risk of side effects compared to similar drugs.

ALZ-101 – Phase 1b study successfully completed

Alzinova's vaccine candidate ALZ-101 has completed it´s Phase 1b study, which began in Q3 2021 and was completed in January 2025. At the end of March 2025, the final results of the study were reported.

The primary objective of the study was to evaluate the safety and tolerability of repeated doses of ALZ-101 in patients with early Alzheimer's disease. The study also included secondary and exploratory endpoints related to immune response, function and cognition, and biomarkers.

Final results and next steps

The final results from the study confirmed a favorable safety and tolerability profile for ALZ-101 at all dose levels. The study also showed that the vaccine candidate induced a strong immune response, which is an important prerequisite for upcoming phase 2 studies.

Efficacy measures linked to function and cognition indicate that ALZ-101 has the potential to slow the progression of the disease, which is further supported by biomarker data. With a successfully completed phase 1b study, Alzinova now has a solid foundation for the next step in the development of ALZ-101, and preparations are underway to initiate a phase 2 study.

ALZ-201 – The next generation of treatments

In parallel with the development of ALZ-101, Alzinova is working to advance the antibody ALZ-201 into clinical development. This monoclonal antibody is based on the same AβCC peptide technology™ and has the potential to become an additional disease-modifying treatment for Alzheimer's disease. This candidate can be a stand-alone treatment but also has the potential to function as a complement to the vaccine. ALZ-201 is currently in preclinical development, where preparations for clinical trials are underway.

Alzinova was founded by researchers working at the MIVAC research center at the University of Gothenburg and GU Ventures AB, and continues to drive innovation in Alzheimer's treatment with a focus on high precision and long-term effect.

Alzinova's unique solution

- ✓ Targeted treatment that specifically attacks and neutralizes neurotoxic peptides (so-called oligomers) which are central to the onset and development of the disease.
- ✓ Vaccine tALZ-101 that stimulates the body to produce antibodies directed against the neurotoxic oligomers.
- ✓ Specific treatment with good effect and reduced risk of serious side effects.
- ✓ Fast, effective and uncomplicated vaccination without long and expensive hospital stays.
- ✓ Can begin treatment early in the disease to counteract the progression of the disease.
- ✓ Monoclonal antibody (ALZ-201) that neutralizes the neurotoxic oligomers and can be used as is or as a complement to the vaccine (ALZ-101).

Other actors within the field

- — Developing treatments that have a broad impact, especially against larger accumulations of Aβ, so-called plaques in the brain, which are believed to contain both toxic and harmless protein.
- — Non-specific treatments which therefore do not only attack and neutralize the neurotoxic oligomers.
- — Often complicated drug treatments that require costly hospital care.
- — Broader non-specific treatments are unlikely to provide sufficient clinical efficacy and may result in serious side effects.

Investment highlights

Vaccine with potential to treat Alzheimer's

Alzinova's lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's disease. A Phase 1b clinical trial has been completed in which ALZ-101 met primary and secondary endpoints. In addition, the study indicates that ALZ-101 has the potential to slow the progression of the disease.

Complementary treatment with First-in-Class antibody

Based on the same technology, Alzinova is also developing a monoclonal antibody, ALZ-201, as a complementary treatment to combat Alzheimer's disease.

First-in-Class potential with favourable safety profile

Data shows that Alzinova's vaccine (ALZ-101) and monoclonal antibody (ALZ-201) have the potential for "First-in-Class" with unique specificity and a more favorable side effect profile than other treatments.

Regulatory progress boost collaborations

Positive feedback from FDA and EMA, as well as other ongoing activities leading up to the next clinical development phase, make Alzinova's candidates attractive for strategic partnerships.

Robust product portfolio

Strong product portfolio and upcoming value-adding activities backed by a patented and proprietary scientific foundation.

Enabling an independent and active life

Alzinova's goal is to enable Alzheimer's patients to live an independent and active life.

A year of clinical breakthroughs and strengthened strategic position

2024 has been a transformative year for Alzinova. We have taken decisive steps in our clinical development, strengthened our strategic position and continued to drive our vision forward with a clear focus on long-term value creation. Our efforts have resulted in important milestones that bring us closer to a treatment that can change the lives of millions of people. By selectively targeting the most harmful forms of amyloid-beta – the oligomers – our treatment differs from today's antibody-based therapies. Our precision and selectivity mean that ALZ-101 has the potential to both improve treatment efficacy while reducing the side effects that characterize current biological therapies. »

Clinical progress paving the way for Phase 2

During the year, we have made significant progress in our Phase 1b study, where the results have been extremely promising. The study is now complete and we can conclude that ALZ-101 has an excellent safety profile and generates a robust, long-lasting and recurrent immune response in patients with AD. In addition, functional and cognitive data suggest that ALZ-101 may have a positive impact on the progression of the disease. These findings are further supported by positive effects on an important neurodegenerative biomarker, NFL. If these results are confirmed in a Phase 2 study, it could represent a significant breakthrough in the treatment of Alzheimer's.

Phase 2 Preparation – The next crucial stage

With Phase 1b completed, we are now working intensively on preparations for Phase 2, which is progressing according to plan. On the regulatory side, we are preparing applications for IND (Investigational New Drug) and Fast Track in the US, in parallel with PRIME in the EU – a strategy that can accelerate development and increase our chances of regulatory priority. At the same time, we are ensuring that the production and supply chain are in phase, through our collaboration with leading manufacturing partners. Our goal is to have all preparations in place in good time for the start of the study.

Financial position and partner discussions

In 2024, we conducted an oversubscribed rights issue, which enabled us to complete the Phase 1b clinical study as planned. At the time of writing, we are in the middle of the subscription period for a rights issue that aims to provide the Company with financial stability and resources to complete the preparations for the upcoming Phase 2 study. In parallel, we are evaluating several financing strategies for the implementation/execution of the Phase 2 study, including strategic partnerships and more traditional capital raising. Our discussions with global pharmaceutical companies are continuing as planned and we have high hopes of finding a strong partner that can support us through Phase 2 and further towards commercialization. The development of ALZ-201, our antibody-based treatment, is also dependent on the right financing structure to best drive the development forward.

ALZ-101 – A potential game-changer in Alzheimer's treatment

ALZ-101 has the potential to be a breakthrough treatment for Alzheimer's disease. By directly targeting the neurotoxic Aβ oligomers that drive the disease, our technology creates new opportunities in a field where current treatments have limited efficacy. Current antibody therapies suffer from high costs, limited efficacy, and serious side effects. With our unique mechanism, ALZ-101 offers a more targeted, safe, and effective treatment, and we look forward to continuing development with the goal of providing patients with a new and better therapeutic option.

»Our discussions with global pharmaceutical companies are continuing according to plan and we have high hopes of finding a strong partner who can support us through Phase 2 and further towards commercialization.«

Ready for the next crucial step

With our clinical progress, a clear strategy and a strengthened financial position, we have entered 2025 with confidence and long-term ambitions. Our focus is on completing a successful Phase 2 study and continuing the work to establish ALZ-101 as a future standard of care.

I look forward to continuing this journey with our dedicated team, investors and strategic partners. Together we have the opportunity to make a real difference in the fight against one of the major public diseases of our time, Alzheimer's.

Thank you for your commitment and trust.

Tord Labuda,
CEO of Alzinova AB

This year's milestones

In 2024, Alzinova has achieved several crucial advances in the clinical development of ALZ-101, the company's vaccine candidate for Alzheimer's disease. The year has been characterized by strong clinical results, regulatory approvals, strengthened financial stability and important management changes, which have created a solid foundation for continued development. Below is a summary of the most important events during the year.

January

The year began with strong data from the primary analysis of the Phase 1b study, where ALZ-101 demonstrated good safety and tolerability, as well as a robust immune response. The results confirmed that the vaccine candidate could be a disease-modifying treatment for patients with early Alzheimer's disease.

February

Alzinova received regulatory approval to evaluate a higher dose of ALZ-101 in the Phase 1b study. This was a strategically important milestone, as a higher dose may optimize the efficacy and safety profile of the treatment in Phase 2 studies.

April

In April, dosing for all patients in the extension portion of the Phase 1b study was completed. An early analysis of the Phase 1b study demonstrated positive changes in biomarkers associated with Alzheimer's disease, further strengthening ALZ-101's potential as an effective treatment.

May

The first patient was treated with the higher dose of ALZ-101 in the Phase 1b study. The aim of this part of the study was to investigate dose-dependent effects and optimize future dosing for the next stage of clinical development.

June

An external safety review was conducted in June and confirmed that ALZ-101 continues to have a good safety profile, providing further support for the upcoming Phase 2 study.

All patients had now been enrolled and started treatment in the high-dose part of the study investigating 400 µg of ALZ-101.

Alzinova participated in the prestigious AAIC 2024, one of the world's most important conferences in Alzheimer's research.

The company's rights issue was oversubscribed, providing capital to finance continued clinical development of ALZ-101 and strengthen the company's position for the next phase.

July

All patients who were to participate in the high-dose part of the phase 1b study had now been included and received their first dose.

August

Alzinova announced that the company has accelerated its work to identify strategic partners for the continued clinical development. This is part of a long-term strategy to secure the resources and expertise to successfully take ALZ-101 to Phase 2 and towards commercialization.

A comprehensive status update was published, in which the company highlighted its clinical progress, financing strategy and the increased activity in partnership seeking.

September

Alzinova appointed Tord Labuda as its new CEO. With a strong background in business development and the pharmaceutical industry, Labuda will play a central role in the company's continued development.

December

Alzinova announced that a final analysis of the extension part of the Phase 1b study confirmed good safety and tolerability, which further strengthens the conditions for proceeding with a Phase 2 study.

Alzinova announced that in January 2025 it will participate in the J.P. Morgan Healthcare Conference in San Francisco, one of the world's largest and most influential conferences in the healthcare sector.

At the end of the year, the company announced that Erik Kullgren had been appointed permanent CFO. Kullgren has been acting CFO since March 2024, and has extensive experience in financial management and capital markets.

About Alzheimer's

Alzheimer's, which is the most common dementia disease, usually starts with mild symptoms, worsens over time, and ends with severe brain damage and death. Alzheimer's causes problems with, among other things, memory, logical thinking, behavior, and personality changes. Symptoms generally develop slowly, get worse over time, and interfere with daily activities. In the end, the body's physiological functions are also affected, and the patient usually dies within about seven years of the established diagnosis.

What causes Alzheimer's?

In Alzheimer's disease, nerve cells in the brain are damaged by abnormal protein deposits that mainly consist of Aβ42[1], a small protein that is also present in a healthy brain. When the Aβ42 molecule clumps together, stable accumulations in the brain, plaques, but also so-called oligomers, are formed.

Oligomers differ structurally from the plaque and, unlike plaques, are highly toxic to brain cells. They damage important functions that cause the contact surfaces between nerve cells, the synapses, to stop functioning normally. The synapses are the places in the brain where electrical and chemical signals are transmitted from one nerve cell to another, and its function is critical for us to be able to remember, react, think, and act. Eventually the nerve cells die.

The disease first affects the parts of the brain that handle short-term memory, but eventually the disease spreads over the entire brain and the patient finds it increasingly difficult to carry out daily tasks. In the end, the patient cannot manage on their own, but requires care and continuous monitoring.

Alzheimer's is a disease that basically anyone can get, and which is strongly age dependent. Over 95% of all cases affect those over 65, and in these cases, there is not a strong genetic component driving the disease.

Alzheimer's is most common in the elderly population, with 1 in 9 people over 65 affected, 65% of whom are women. However, about 5% of cases are diagnosed at an earlier age.

[1] *A peptide (part of a protein) produced by the body that can aggregate in the brain and cause Alzheimer's disease.*


Every 5th
second, someone
is affected by
Alzheimer's
disease

Alzinova's treatments

The market for the treatment of Alzheimer's disease is large as there is currently no effective treatment to cure the disease. Alzinova's approach, to develop a therapeutic vaccine that specifically targets the toxic accumulations of amyloid-beta in the form of oligomers in the brain, has several advantages over other treatment methods. Other actors have developed or are developing treatments that target larger accumulations of amyloid-beta, known as plaques in the brain, which are believed to contain both toxic and harmless protein. It has been shown that these are unlikely to provide sufficient treatment effect and can result in serious side effects.

In contrast, Alzinova has managed to identify a treatment method that could specifically target the toxic protein in the brain, amyloid-beta oligomers, one of the underlying causes of Alzheimer's disease.

About ALZ-101

ALZ-101 – An innovative vaccine candidate with strong clinical results
ALZ-101 is an active, therapeutic vaccine candidate specifically targeting Aβ oligomers, the neurotoxic accumulations in the brain that are thought to drive the development of Alzheimer's disease. Vaccination with ALZ-101 induces the body to generate its own antibodies against these oligomers, which may protect the brain's synapses and potentially slow the progression of the disease. The approach is also expected to have a lower risk of side effects, such as bleeding and edema, that are often associated with treatments targeting amyloid plaques.

Alzinova has established a robust and quality-assured manufacturing process for ALZ-101 on an industrial scale, which is an important prerequisite for upcoming phase 2 studies and further development towards a future market introduction.

Clinical progress in 2024
In 2024, Alzinova reported significant clinical progress in the now completed Phase 1b study of ALZ-101. In November 2024, the company announced that all study participants had completed the final visit in the study and that data analysis was ongoing. Earlier in the year, Alzinova reported positive results from the extension part of the study, where ALZ-101 demonstrated a continued strong safety profile and a high immune response.

Patients in the extension (Part B) were treated with 250 µg of ALZ-101 for a 20-week period, and the results confirm long-term safety and tolerability. Cognitive data from the study indicate that ALZ-101 can affect the course of the disease, which is an important signal for phase 2 studies.

To further optimize the dosing for phase 2, Alzinova has also conducted an additional study (A2), where a higher dose of ALZ-101 (400 µg) has been evaluated. Preliminary results show that this dose also has a good safety and tolerability profile, which strengthens the possibilities to maximize the treatment effect in future studies.

In March 2025, Alzinova announced that the primary and secondary endpoints of the Phase 1b study – safety, tolerability and immunogenicity – had been met. In addition, the exploratory efficacy measures showed a stable disease picture with no signs of deterioration. Alzinova's Phase 1b clinical study was thus completed.

The combined results from the Phase 1b study provide a solid foundation for the continued clinical program and position ALZ-101 as a potential game-changer in Alzheimer's treatment. With a selective and precise approach, ALZ-101 has the potential to fill an important gap in the treatment landscape and provide patients with a safer and more effective treatment strategy.

About ALZ-201

ALZ-201 is a monoclonal antibody based on Alzinova's AβCC technology developed to specifically target and neutralize the neurotoxic forms of the peptide Aβ42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease. The antibody ALZ-201 does not bind to other, harmless, forms of Aβ such as fibrils and plaques, as proven in preclinical studies on human material. The preclinical results indicate that it is a small amount of Aβ42 oligomers that are responsible for the main toxic effect in Alzheimer's disease, and that specificity for this form is likely necessary to obtain a good therapeutic effect of an antibody treatment. The preclinical results support that ALZ-201 has the potential to stop or slow the progressive deterioration of cognition seen in patients with Alzheimer's disease.

Alzinova is currently developing a humanized version of ALZ-201 for Phase 1 clinical trials in patients with Alzheimer's disease. A passive immunotherapy with ALZ-201 could be developed as an effective complement and disease-modifying alternative to the therapeutic vaccine ALZ-101. The Company's research demonstrates that both ALZ-201 and the ALZ-101 vaccine have First-in-Class potential, and clinical results from other players in the field strengthen the Company's strategy.

ALZ-101 – Completed clinical phase 1b study

Alzinova's vaccine candidate ALZ-101 has now completed a full Phase 1b study, the results of which were communicated in March 2025. The primary objective was to evaluate the safety and tolerability of repeated doses of ALZ-101 in patients with early Alzheimer's disease. The study also included secondary and exploratory endpoints related to immune response and biomarkers.

Study design

The Phase 1b study was randomized, double-blind, and placebo-controlled and was conducted in several parts:

Part A: Investigated two dose levels of ALZ-101 (125 µg and 250 µg) and placebo. 20 patients received active treatment while 6 patients received placebo.

Part A2: An additional part to evaluate a higher dose (400 µg), which was approved and started in 2024. 6 patients were treated for 16 weeks.

Part B: An extension part, where patients from Part A were treated with 250 µg ALZ-101 for 20 weeks, followed by 48 weeks of follow-up.

Results

The results showed that ALZ-101 continues to have a good safety profile and tolerability. Patients receiving ALZ-101 developed a strong immune response, with antibody levels increasing with dosing.

Additionally, preliminary cognitive data and biomarkers indicate that ALZ-101 may positively impact disease progression, providing strong support for upcoming Phase 2 studies. The evaluation of the higher dose (400 µg) also demonstrated good safety and tolerability, providing important information for dose optimization in future studies.

With these positive results from Phase 1b, Alzinova has a solid foundation for the next step in the clinical development of ALZ-101 and is now planning for the upcoming Phase 2 study.



AD: Alzhemiers Disease.

Alzinova's competetive advantages



Based on statistics from Statistics Sweden on the Swedish healthcare system, and that the two treatments have equivalent clinical efficacy, total treatment time and drug cost.

Alzinova is developing a vaccine candidate to treat Alzheimer's disease. The vaccine, unlike other treatments such as antibodies, is expected to require only a few doses a year rather than as often as every two weeks. In addition, it can be given to patients in a very time-efficient way through a simple injection in primary care or at home by a nurse. Other treatments are time-consuming and require hospital care.

Treating patients with therapeutic antibodies, sharply increases societal costs, resulting in fewer patients being treated with an antibody treatment. With Alzinova's vaccine, compared to antibody treatment, healthcare and societal costs can be reduced, which creates the opportunity for more people to receive care.

Business model

Alzinova's business model is to drive projects into clinical development with the aim of documenting that the drug candidates are safe and well tolerated and securing proof-of-concept, to demonstrate efficacy in patients with Alzheimer's. Based on clinical data, the Company intends to identify one or more strategic partners who have the resources and in-house expertise to conduct the studies needed for registration and commercialization. This can be done through out-licensing with a partnership where the Company jointly with the partner takes the drug to market, or through a complete acquisition of the drug candidate for further development.

Out-licensing
A common option for development companies like Alzinova is to out-license projects to one or more pharmaceutical companies. Either these can be granted exclusivity in a limited market and agreements are made with several partners to cover the market globally, or there is a global partner that takes the drug to the entire world market. A typical arrangement for out-licensing is an initial fee and then future installments linked to predefined milestones during the continued development, the regulatory process and commercialization, as well as significant revenues linked to future drug sales.

The Company has so far taken several important steps towards out-licensing and commercialization. Data shows "First-in-Class" potential, which is very attractive for partnering. With positive results in both of the Company's drug projects, ALZ-101 and ALZ-201, several options are available. The primary option prior to the Phase 2 study is to out-license the ALZ-101 vaccine to a larger pharmaceutical company, and another option is for Alzinova to take ALZ-101 through Phase 2 and then out-license it to a partner. For the ALZ-201 antibody, this could be out-licensed already during the preclinical phase, or alternatively after Phase 1b studies. The Company's focus going forward is on business development with several ongoing dialogues in parallel with clinical development of the project portfolio.

The market for Alzheimer's drugs

Every year, around 10 million people worldwide develop some form of dementia, of which Alzheimer's disease accounts for around 60–70%. Today, it is estimated that there are around 55 million patients with dementia in the world, even though it is difficult to diagnose dementia. Therefore, it is estimated that there is a large hidden number and that the figure is significantly higher. This number is expected to increase to more than 130 million by 2050. It is estimated that more than 30 million people worldwide currently have Alzheimer's disease and the number is expected to triple by 2050[2].

The cost to society of dementia was estimated in 2019 at USD 1.3 trillion annually, a figure that is set to more than double by 2030.[3] The cost of Alzheimer's drugs, which only relieve symptoms, is around USD 6 billion annually. While the first disease-modifying drugs have recently been approved in the US, Japan and China, there is still a very long way to go to truly treat and prevent the progression of Alzheimer's disease.

The sales and revenue potential of a new effective disease-modifying drug is therefore significant even if it would only initially have a limited market share. By 2026, Alzheimer's disease drugs are expected to be represented among 2 out of 7 expected top sellers (pharmaceutical companies), with an expected annual sales of USD 1.7-4.5 billion[4]. The reason that the sales estimates are initially relatively low is that there have been no good medical alternatives. With effective treatment alternatives coming to the market, such as Alzinova's drug, the Company estimates that annual sales could multiply compared to today.

Annual sales volume for disease-modifying therapies for Alzheimer's disease is projected to increase from USD 2.1 billion in 2020 to USD 13.5 billion by 2030 in the eight largest markets. An approved disease-modifying therapy for Alzheimer's disease has the potential to generate peak annual sales exceeding USD 10 billion[5].

[2] World Health Organization (WHO) – Facts about Dementia, March 2023.
[3] World Alzheimer's Report, 2021.
[4] Drugs to watch report, 2022.
[5] US, Germany, France, UK, Italy, Spain, Japan, China. GlobalData, Pharma, June 7, 2023.

Our vision

»To enable patients to live independent and active lives without the impact of Alzheimer's disease by developing new treatments that modify the disease.«

Our goals

Goals for 2025

Accelerate the partnering process
- Secure funding for phase 2 studies, primarily through partnerships.

Start of the Phase 2 study with ALZ-101, including
- Complete regulatory applications (IND and Fast Track in the US, PRiME in the EU).
- Finalise study design and establish collaboration with contract research organization.
- Manufacturing of drug product.
- Establish collaborations with leading clinics in the US and Europe.
- Begin patient recruitment and dose the first patient.

Further development of ALZ-201 (the antibody project)
- Complete preclinical testing and initiate toxicology studies.
- Prepare ALZ-201 for Phase 1 clinical trial.

Our long-term goal

»Our long-term goal is to develop a disease-modifying therapeutic vaccine for the treatment and prevention of the development of Alzheimer's disease.

A long-acting drug will make it possible for patients to live an active and independent life without the influence of the disease.«

Management

Tord Labuda

Position
Chief Executive Officer since 2024.

Background
Tord has over 15 years of extensive experience in senior positions in the pharmaceutical industry. His expertise covers the entire pharmaceutical chain, from early discovery to regulatory approval and product launch. During his career, Tord has held several high-profile positions within LEO Pharma, including Vice President & Head of Global Clinical Development, President and Japan Representative Director, and Vice President of R&D Asia-Pacific. Most recently, Tord worked as a senior consultant in the biotechnology, medical device and pharmaceutical sectors. His broad international experience in the pharmaceutical industry, combined with his knowledge of multiple therapeutic areas and global markets, makes him an experienced and strategic leader in the industry.

Education
Master's degree in molecular biology and a doctoral degree (PhD) in immunology from Lund University.

Ongoing assignments
Board member of NanoEcho AB.

Holdings in the Company
80,000 shares and 1,000,000 warrants as of April 8, 2025.*

Anders Sandberg

Position
Chief Scientific Officer since 2015.

Background
Anders is one of Alzinova's founders and was also the Company's CEO during a transition period. He has extensive experience in protein science, with a particular focus on protein stability and folding. Since 2007, Anders has worked with neurotoxic peptide aggregates, which has led to the development of ALZ-101 and ALZ-201. Anders is also a co-inventor of Alzinova's A CC technology and has been an alternate member of the board since 2011.

Education
PhD in chemistry - specializing in biochemistry.

Ongoing assignments
No other ongoing assignments.

Holdings in the Company
126,644 shares and 500,000 warrants as of April 8, 2025.*

** Includes own holdings, holdings of related and controlled companies or holdings in endowment insurance accounts.*

Erik Kullgren

Position
CFO since 2024.

Background
Erik has more than 25 years of experience in international finance and corporate administration across various sectors. His experience includes financial positions within Swedbank Robur, as well as roles as CFO and CEO at Dunross & Co AB, a privately held investment company, and CEO of Reguity Group AB. Erik also has experience as interim CFO in several companies.

Education
MSc in Business Administration from the School of Economics and Business Administration at the University of Gothenburg.

Ongoing assignments
Board member of Apprecia AB, NVR Kapitalförsäkring AB and Stiftelsen Dunross & Co AB.

Holdings in the Company
50,000 shares and 500,000 warrants as of April 8, 2025.*

Stefan Pierrou

Position
Vice President R&D Projects since 2021.

Background
Stefan has 25 years of experience in pharmaceutical development and research. He has worked as a preclinical research manager and project manager for early clinical studies, with a focus on developing drug candidates for clinical trials and beyond. Stefan has held several senior roles in research and development at AstraZeneca, where he worked with both project management and strategic leadership. He also works as a senior consultant and supports smaller biotechnology and pharmaceutical development companies.

Education
MSc in Chemical Engineering, PhD in Molecular Biology.

Ongoing assignments
CEO, ESP Life Science Consulting AB.

Holdings in the Company
24,760 shares and 250,000 warrants as of April 8, 2025.*

Sebastian Hansson

Position
Business Development Director since 2023.

Background
Sebastian has 15 years of experience in pharmaceutical research and clinical development, including work with CROs and GMP production of active pharmaceutical ingredients (APIs). He has extensive experience in startups and business development. Before joining Alzinova, he was Chief Operating Officer at SWIPP AB, Project Manager and Key Account Manager at Polypeptide Group, and Business Development Manager at Solve R&C.

Education
MSc in chemistry, PhD in molecular biophysics, MBA, certified board member.

Ongoing assignments
Board member of Bulb Intelligence AB, Tyto Competitive Intelligence Solutions AB and Scientific Intelligence Consulting Öresund AB.

Holdings in the Company
84,882 shares and 250,000 warrants as of April 8, 2025.*

** Includes own holdings, holdings of related and controlled companies or holdings in endowment insurance accounts.*

Board of Directors

Julian Aleksov

Position
Chairman of the Board since 2023.

Background
Julian has more than 25 years of experience in finance and international business development within the pharmaceutical and technology industry, including from Oasmia Pharmaceutical AB. Julian is an entrepreneur who has run his own companies for many years in several different business areas, primarily pharmaceutical development. He is an active investor and through companies also a major owner in a number of listed companies.

Education
Economist.

Ongoing assignments
Board member of Maida Vale Capital AB and Hunterhex AB.

Holdings in the Company
14,632,418 shares as of April 8, 2025.*

Anders Blom

Position
Board member since 2021.

Background
Anders has more than 25 years of experience in international finance and business development within the pharmaceutical and medical device industry. His experience includes Pharmacia & Upjohn, Q-Med AB, partner and CEO at the venture capital company Nexttobe AB and EVP and CFO at Oasmia Pharmaceutical AB. In addition, Anders has extensive board experience from the pharmaceutical and technology sectors.

Education
Bachelor's degree in business administration at Uppsala University.

Ongoing assignments
Chairman of the Board of Peptonic Medical AB, Rosland Nordic AB and board member of Terranet AB, Hunterhex International Inc, Hunterhex AB and Wonderboo Holding AB.

Holdings in the Company
14,632,418 shares as of April 8, 2025.*

** Includes own holdings, holdings of related and controlled companies or holdings in endowment insurance accounts.*

Clas Malmeström

Position
Board member since 2015.

Background
Clas is a senior physician at the MS Center, Neurology, and a unit senior physician at the Laboratory for Clinical Immunology at Sahlgrenska University Hospital in Gothenburg. Since 2001, he has conducted research in Multiple Sclerosis (MS) at the hospital's MS Center and the Department of Clinical Neuroscience, University of Gothenburg. In addition to academic research, he has participated in several clinical drug trials for MS led by Biogen-Idec, Merck, Novartis, Roche and Sanofi, several of which resulted in today's standard treatments for MS.

Education
Medical doctorate, senior physician Neurology and Clinical Immunology.

Ongoing assignments
No other ongoing assignments.

Holdings in the Company
20,000 shares as of April 8, 2025.*

Per-Göran Gillberg

Position
Board member since 2020.

Background
Per-Göran has 35 years of experience in the pharmaceutical industry. He has broad experience in pharmacology and neuropharmacology from Kabi/Kabi Pharmacia, Pharmacia/Pharmacia & Upjohn and AstraZeneca. Per-Göran is the founder of Albireo AB and was previously VP Development for Albireo Pharma Inc. He is also affiliated with the Department of Translational Alzheimer Neurobiology at the Karolinska Institute in Stockholm.

Education
PhD in medical science, adjunct professor in neuroscience at Uppsala University.

Ongoing assignments
Board member of Dicot AB. Adjunct to the Center for Alzheimer Research at Karolinska Institutet. Chairman of the Board of Vissboda Gård AB.

Holdings in the Company
176,321 shares as of April 8, 2025.*

** Includes own holdings, holdings of related and controlled companies or holdings in endowment insurance accounts.*

Carol Routledge

Position
Board member since 2018.

Background
Carol has over 30 years of experience in pharmaceutical and biotechnology companies. She has held key roles at GSK Biopharmaceuticals, in the areas of immunoinflammatory diseases and neuroscience. She most recently managed a dementia fund focusing on disease-modifying mechanisms for the treatment of all types of dementia. Carol was also Head of Research at Alzheimer's Research UK and previously Chief Medical and Scientific Officer at Small Pharma Ltd. She is now an independent consultant in biomedical research.

Education
PhD in neuropharmacology.

Ongoing assignments
Steering Committee member and Advisor of EDoN, Alzheimer's Research UK, Advisory Board of Ro5.AI, London, UK, Advisory Board of Cognetivity Neurosciences Ltd, Vancouver and Honorary Professor & EIR, Exeter University, UK.

Holdings in the Company
No shares as of April 8, 2025.*

Anders Waas

Position
Board member since 2018.

Background
Anders has held several senior roles in Astra, AstraZeneca, CV Therapeutics, Actogenics and Tikomed AB. He has previous experience in corporate management, business development and pharmaceutical development.

Education
Dentist (DDS).

Ongoing assignments
Chairman of the Board of Sobrera Pharma AB, and SiMSen Diagnostics AB. Board member of Transmed Gothenburg AB, Toleranzia AB, Anders Waas AB, Nexocure Therapeutics AB, Xandrax AB, and CerInvent AB.

Holdings in the Company
No shares as of April 8, 2025.*

** Includes own holdings, holdings of related and controlled companies or holdings in endowment insurance accounts.*

Administration report

The Board of Directors and the Chief Executive Officer of Alzinova AB (corporate identity number: 556861-8168) hereinafter referred to as Alzinova or the Company, hereby submit the Annual Report for the financial year 2024. Alzinova is a public limited liability company.

Alzinova is a Swedish biopharmaceutical company specialising in the treatment of Alzheimer's disease. The Company's proprietary AβCC-peptide™ technology enables the development of disease modifying therapies that with high precision could target the toxic accumulations of the peptide amyloid-beta, so-called oligomers, which are central to the onset and development of the disease. The vaccine candidate ALZ-101 is under clinical development, and the full Phase 1b study in patients with early Alzheimer's disease has now been completed. The study began in the third quarter of 2021 and was conducted in three parts (A, B, and A2). Results show that ALZ-101 has a favorable safety and tolerability profile as well as a robust and long-lasting immune response. Moreover, exploratory efficacy measures indicate stable cognitive function over time. To optimize dosing ahead of further development, a high-dose part of the study was conducted, confirming that the 400 µg dose is also safe and well tolerated. The results from the entire study support continued clinical development, and preparations for a Phase 2 study are ongoing. In parallel, the Company is developing the antibody ALZ-201, based on the same AβCC peptide technology™. ALZ-201 is in preclinical development, and a humanized version has been produced in preparation for planned Phase 1 clinical trials.

Alzinova was founded by researchers from the MIVAC research center at the University of Gothenburg, in collaboration with GU Ventures.

The Company has its registered office in Gothenburg.

Significant events during the financial year 2024

First quarter

- Alzinova announced the full analysis of the data from part A of the phase 1b clinical trial, with the vaccine candidate ALZ-101. The analysis confirmed the positive results previously reported. Given the favourable safety profile, the Company applied for an extension to the study to evaluate a higher dose level. The extension was included to optimise the design of the upcoming phase 2 study.
- In February, the Company received regulatory approval to evaluate a higher dose of the vaccine candidate ALZ-101 in the ongoing phase 1b study.
- Erik Kullgren was appointed interim CFO.

Second quarter

- All patients in the extension part (part B) of the phase 1b study were dosed with the last dose of the Alzheimer's disease vaccine candidate ALZ-101 in April.
- An in-depth analysis of data from part A1 of Alzinova's phase 1b study with the vaccine candidate ALZ-101 was conducted in April. The analysis indicated that patients with the higher antibody levels after vaccination have a positive effect on biomarkers associated with Alzheimer's disease.
- Alzinova's CEO, Kristina Torfgård, informed the Board of Directors at the end of April of her wish to step down as CEO of the company.
- Alzinova's Board of Directors decided, with the support of authorisation from the Annual General Meeting 2023, on a rights issue of shares of approximately SEK 34.4 million.
- In May, the first patient was dosed in the final cohort (part A2) of the phase Ib study. Part A2 aims to evaluate a higher dose of ALZ-101.
- The minutes of the Annual General Meeting were published. All proposals for resolutions were adopted by the meeting. Lena Degling Wikingsson left the Board of Directors in connection with the AGM and the Board subsequently consists of Julian Aleksov (Chairman), Anders Blom, Per-Göran Gillberg, Clas Malmeström, Carol Routledge and Anders Waas.
- Alzinova announced that a new external safety review of part A2 of the Company's phase 1b clinical trial has been completed - with a positive assessment to continue the study as planned.
- Enrolment of patients in Alzinova's part A2 of the phase 1b study was completed at the end of June.
- Alzinova announced a change of Certified Adviser and Liquidity Provider. The changes came into effect on 1 July 2024.
- Alzinova's rights issue was oversubscribed with a subscription rate of approximately 106%. The company raised approximately SEK 34.4 million before deduction of issue costs. No underwriting commitments were utilized.

Third quarter

- All patients in part A2 of the phase 1b study had received the first dose of ALZ-101 by July.
- The Board of Directors decided to appoint Board member Carol Routledge as acting CEO of Alzinova from August 1, 2024, until a permanent CEO is recruited.
- Alzinova published further details of the data presented in a poster presentation at AAIC in July 2024.
- Alzinova updated the market that the Company has accelerated the partnering process. Among other things, the Company has hired a well-reputed American advisor to assist the Company in identifying a partner.
- In August, the Company updated the market on the status of the various parts of Alzinova's phase 1b study.
- In September, the first study participant had successfully completed the entire phase 1b study with ALZ-101.
- The Board appointed Tord Labuda as the new CEO of Alzinova, effective 1 October 2024.

Fourth quarter

- All patients in the high dose part (part A2) of the phase 1b study received their last dose.
- Alzinova announced that patient data from the extension part of the phase 1b study with ALZ-101 is being processed. Results are expected around the end of November-December 2024.
- The company participated in BIO-Europe 2024, one of Europe's largest partnering conferences in life science, where it met a large number of potential partners.
- Alzinova reported continued promising results from its phase 1b clinical trial with the vaccine candidate ALZ-101 in Alzheimer's disease. Analysis of data from patients who participated in the study for at least 84 weeks showed, among other things, that ALZ-101 continues to have a good tolerability and safety profile. The positive results provide strong support for continued clinical development of ALZ-101.
- Alzinova appointed Erik Kullgren as permanent CFO.

Significant events after the end of the financial year 2024

- Alzinova participated between January 13-16, 2025 at the J.P. Morgan Healthcare Conference in San Francisco, where management met with a large number of potential partners and investors to present the company's latest positive clinical Alzheimer's data and strong results from the phase 1b study with the vaccine candidate ALZ-101.
- The Company announced that a strategic decision has been made to appoint a CMO on site at the Company's head office in Gothenburg, primarily with the aim of being able to maintain even closer dialogue with the business's R&D team and management team as Alzinova enters the next development phase.
- Alzinova announced that all study participants have completed the final visit in the phase 1 study. All data points will then be processed, analyzed and compiled. The final results for the entire study period are planned to be communicated by the end of March 2025.
- The Company announced that data had been obtained for the treatment arm in which patients were treated with 400 µg in the Company's Phase 1b study. This treatment arm also demonstrated good safety and tolerability.
- A communiqué from the Extraordinary General Meeting stated that a resolution had been passed to adopt an incentive program (LTIP 2025:1) consisting of warrants for members of management, other employees, and key consultants of the Company. In brief, the incentive program entails an issue of up to 4,000,000 warrants. Each warrant entitles the holder to subscribe for one new share in the Company during the period from 15 March 2027 through 31 March 2027, at a subscription price corresponding to 200 percent of the volume-weighted average price of the Company's share during the ten (10) trading days immediately preceding the first offer to acquire warrants, but not less than the quota value of the share.
- Alzinova announced that the final analysis of data from the clinical Phase 1b study with the vaccine candidate ALZ-101, which included patients with early Alzheimer's disease, had been completed. The study's primary and secondary objectives – safety, tolerability, and immunogenicity – were met. Furthermore, the exploratory efficacy measures indicated a stable disease profile with no signs of deterioration. The clinical Phase 1b study conducted by Alzinova was thus concluded.
- On April 2, 2025, the Board of Directors, with the support of authorization, decided to carry out a rights issue of shares, which, if fully subscribed, will provide the Company with approximately SEK 35.7 million before issue costs. Prior to the rights issue, the Company received subscription commitments and issue guarantees corresponding to 85 percent of the rights issue. The main purpose of the Rights Issue is to provide the Company with capital to complete the preparations for the vaccine candidate ALZ-101 for the upcoming clinical study while existing partner dialogues with Big Pharma companies progress.
- The company announced that the incentive program LTIP 2025:1 has been implemented and that Alzinova's board, in accordance with the guidelines decided by the general meeting, has decided to transfer 3,250,000 warrants to the participants. The program includes a maximum of 4,000,000 warrants. If all warrants are fully exercised, the dilution effect amounts to approximately 4.29 percent of the share capital and votes in the Company.
- Alzinova announced that members of the Company's board and management and other existing shareholders, in addition to previously announced pre-subscribers and underwriters, have submitted declarations of intent to subscribe for the rights issue for a total of approximately SEK 1.0 million.

Revenues and results

During the year, the company has mainly continued to invest in the development of ALZ-101, a vaccine against Alzheimer's disease, which is in clinical phase 1b. The clinical study has been completed with good results in the first quarter of 2025. The company has also continued its development for clinical studies of the antibody ALZ-201, with the aim of treating and also preventing the progression of Alzheimer's disease.

Net sales in 2024 were SEK 0 million (0), and the Company is not expected to generate revenue until the Company's products have progressed further in their development phase. Operating profit for the year amounted to approximately SEK -20.5 million (-16.5).

During the year, the Company's total costs amounted to approximately SEK 37.2 million (36.4), of which approximately SEK 16.8 million (19.6) were capitalized as development costs regarding the Company's products and were recorded as intangible non-current assets. The increase in development costs has continued according to the Company's plan.

Cash flow

Cash flow from operating activities, including changes in working capital for the year, amounted to approximately SEK -20.3 million (-15.2).

Cash flow from investing activities amounted to approximately SEK -16.8 million (-19.6) and consisted of capitalized development costs.

Cash flow from financing activities amounted to approximately SEK 30.5 million (SEK 24.8 million), and was generated through the oversubscribed rights issue carried out during the second quarter of approximately SEK 40.2 million before costs. Total issue costs of approximately SEK 9.6 million departed from this.

Financial Position

At the end of the year, the Company had cash balances of approximately SEK 15.5 (22.0) million.

The financial information has been prepared on a going concern basis. In preparing the annual report, management and the board have based their assumptions on existing cash and cash equivalents and expected financing.

The clinical development requires continued and significant financing for Alzinova. On April 2, the Board of Directors decided to carry out a rights issue that, if fully subscribed, will provide the Company with SEK 35.7 million before issue costs. The issue is guaranteed by subscription commitments and guarantee commitments of approximately 85%. The issue will provide the Company with funds that ensure that the Company can complete its preparations for the planned clinical phase 2b study and continue with the development of the antibody ALZ-201. During the first quarter of 2025, the Company received a loan commitment of SEK 10 million on market terms from Maida Vale Capital AB, the Company's largest individual shareholder. For 2025, the Company also has the opportunity to reprioritize operations based on the capital available in the Company, which is why the Board of Directors believes that the conditions for continued operation are met.

To implement the planned Phase 2 study, we are evaluating several financing strategies in parallel, including strategic partnerships and more traditional capital raising. Management is aware that there are uncertainties in the estimation of future cash flows, but sees this risk as manageable and is continuously working to overcome it.

Development of the Company's operations, profit/loss and position

KSEK	2024	2023	2022	2021	2020
Net sales	0	270	-	-	-
Result after financial items	-20,553	-16,480	-13,088	-7,552	-6,500
Earnings per share before/after dilution, SEK	-0.31	-0.41	-0.54	-0.48	-0.78
Total capital	133,226	123,189	111,621	91,691	100,816
Average number of full time employees	5	5	4	3	3
Equity ratio, %	92.9	92.4	94.5	96.5	95.2

Earnings per share: Result for the year, divided by the number of shares at the balance date
Equity ratio: Total equity diveded by total capital

Proposed appropriations of the Company's profit or loss

The Board of Directors and the CEO propose that the funds available, SEK -10,600 thousand, be allocated as follows:

KSEK	2024
Retained result	-175,090
Share premium	185,043
Result for the year	-20,553
Total	**-10,600**
To be carried forward	-10,600
Total	**-10,600**

As regards the Company's results and position in general, reference is made to the subsequent income and balance sheets with accompanying notes.

Corporate structure and shareholding

Alzinova has no subsidiaries and is not part of any group. Neither does the Company hold any shares.

The Share

The Alzinova share was listed on the Spotlight Stock Market on November 25, 2015. As of March 11, 2019, the Company is listed on Nasdaq First North Growth Market in Stockholm. The company has one class of shares. The share carries one (1) vote per share. Each share carries equal rights to a share in the Company's assets and earnings. As of December 31, 2024, the number of shares in Alzinova amounted to 89,165,640. The share's quota value amounts to SEK 0.263 per share.

Rights Issues

In 2024, the Company carried out an oversubscribed rights issue that provided the Company with approximately SEK 30.5 million after deduction of issue and guarantee costs of approximately SEK 9.6 million. The issue resulted in the Company's shares increasing by 44,634,195 shares to a total of 89,165,460 shares and with a total share capital of SEK 23,450,516. For shareholders who did not exercise their warrants, the dilution amounted to approximately 50% based on the total number of shares in the Company.

Largest owners as per 29 December 2024

Owner	No. of shares/ votes	Capital, %
Försäkrings AB Avanza Pension	15,262,718	17.12
Maida Vale Capital AB	14,632,418	16.41
Nordnet Pensionsförsäkring AB	3,117,077	3.50
Futur Pension	2,850,517	3.20
Hunter Capital AB	2,222,222	2.49
Patrik Ahlvin	1,900,000	2.13
Özlem Erdogdu Gül	1,414,500	1.59
Ålandsbanken	1,340,954	1.50
Sara Gjertz	1,140,000	1.28
Moll Invest AB	1,051,990	1.18
Total other owners	44,233,064	49.61
Total all owners	**89,165,460**	**100.00**

Long-term share-based incentive programs

At the extraordinary general meeting on March 7, 2025, it was decided, in accordance with the board's proposal, to introduce a long-term incentive program (LTIP 2025:1). The program includes a maximum of 4,000,000 warrants and is aimed at all employees and key employees who are active on a consulting basis. If all warrants are fully exercised, the dilution effect amounts to approximately 4.29 percent of the share capital and votes in the Company. After the offering was completed, all 8 participants have subscribed for a total of 3,004,000 warrants, corresponding to approximately 92 percent of the total number of available warrants within the framework of the program.

Risk factors

Alzinova maintains procedures to continuously identify and manage risk factors. The primary risk factors that affect the Company are set out below.

Market and business-related risks

The Company's drug candidates
The company's primary focus is the vaccine candidate ALZ-101 and the antibody ALZ-201.

During the first quarter of 2025, ALZ-101 completed a clinical phase 1b study in humans. The clinical study showed good safety and tolerability as well as satisfactory results on the immune response. The company therefore plans to continue the clinical development through a clinical phase 2b study. Should the results of the clinical phase 2b study show an unsatisfactory effect, it may mean that the Company will have to terminate the project.

The company is also developing the antibody ALZ-201, which is in the early preclinical phase and based on the same technology as the vaccine candidate ALZ-101. There is also a risk that studies of ALZ-201 in themselves do not provide satisfactory results. If the risk materializes, it may mean that the Company will have to discontinue the development of ALZ-201.

If one or both projects had to be terminated, this would mean that the Company would not be able to generate revenue from the project, which would have an impact primarily on the Company's sales, earnings and financial position.

Commercialization
The company has not yet commercialized its projects, for example through license agreements, partnerships or independently developed or launched any drugs and has therefore not conducted any sales or generated any revenue. If the Company does not succeed in commercializing its projects, the Company will not be able to generate revenue and will then remain completely dependent on externally provided capital. If the Company does not succeed in commercializing its projects, it may have an impact primarily on the Company's sales and earnings.

Key people and recruitment
When commercializing its projects, the Company is dependent on the organization maintaining competence to carry out all steps in the development of the projects. As the Company's organization is limited, the Company is particularly sensitive to the loss of its employees. Loss of certain specific key personnel and failure to recruit people with sufficient competence for the clinical studies may make it more difficult to carry out the necessary studies and achieve commercialization of the projects.

Suppliers and manufacturers
The company is dependent on collaborations with suppliers and manufacturers. The part of the business that is carried out by partners is not considered to be able to be performed by the Company. There is a risk that the Company's partners will be forced to discontinue their cooperation with the Company. There is also a risk that the Company's suppliers and manufacturers do not fully meet the quality requirements set by the Company. If the Company's collaborations could no longer continue, or if they do not live up to the quality requirements set by the Company, this would result in delays in the development program. The Company continuously evaluates its direct as well as indirect suppliers and conducts active work to minimize and, as far as possible, eliminate external influences on the Company's operations.

The Company currently operates in an environment with a very uncertain geopolitical world situation and it is difficult to say how this will affect the Company's long-term development.

The general global economic situation is a major challenge for all companies to deal with, mainly through inflationary cost increases. This risk is continuously monitored through a high level of cost awareness.

Legal and regulatory risks

Preclinical and clinical studies
Before a drug can be launched on the market, the safety and efficacy of a treatment for humans must be ensured for each individual indication, which can often be demonstrated through preclinical studies in animals and clinical trials in patients. Alzinova may need to conduct more extensive studies than the Company currently assesses. There is also a risk that the partners conducting the preclinical and clinical trials will not be able to maintain the clinical and regulatory quality required for any future out-licensing, partnership, sale or regulatory approval.

If the Company needs to conduct more extensive studies than what the Company currently assesses, this may lead to increased costs or delayed revenues. If the partners who carry out the preclinical and clinical studies are unable to maintain the clinical and regulatory quality required for any future out-licensing, partnership, sale or approval from authorities, this may lead to delays in preclinical and clinical studies for the Company and thus no commercialization.

Intellectual Property Rights
The value of the Company is largely dependent on the ability to obtain and defend patents. There is a risk that the Company's patents will not be granted on patent-pending inventions, that patents will be circumvented by generic companies in particular, that patents will be invalidated in court, or that the patent period will expire before successful commercialization has taken place. If the Company does not obtain or succeed in defending its patents, the Company's competitors are given the opportunity to commercialize their own products without hindrance of patent rights and thereby affect the Company's sales potential.

Financial risks

Liquidity risk
Even if the Company succeeds in commercializing its projects, the Company's and the future commercialized projects' revenue potential is uncertain. If the Company does not reach a satisfactory revenue potential, there is a risk that revenues will not be generated in whole or in part. If revenues do not exceed the Company's costs, the Company will continue to be dependent on externally provided capital. If the Company is unable to obtain external capital to a sufficient extent, it will have a negative impact on the Company's financial position, which means that the Company's operations will not be able to be conducted at the planned pace. The company manages this risk by preparing well in advance for external financing in the form of issues, grants or other capital. Furthermore, the Company continuously monitors cash flow to reduce liquidity risk.

Financial market risk
Financial market risk consists primarily of currency risks arising from business transactions in foreign currency. The company's currency risk is affected by flows from purchases primarily in EUR and USD.

Income Statement

KSEK	Notes	Jan-Dec 2024 12 months	Jan-Dec 2023 12 months
Net sales		-	-
Other operating income		30	270
Own work capitalized	5	16,781	19,604
		16,811	**19,874**
Operating expenses			
Other external expenses	2	-26,665	-27,097
Personnel expenses	3	-10,528	-9,299
Total operating costs		**-37,193**	**-36,396**
Operating result		**-20,381**	**-16,522**
Result from financial items			
Interest income		65	140
Interest expenses		-236	-98
Result after financial items		**-20,553**	**-16,480**
Result before tax	4	**-20,553**	**-16,480**
Result for the year		**-20,553**	**-16,480**

Balance Sheet

KSEK	Notes	31 December 2024	31 December 2023
ASSETS			
Fixed assets			
Intangible assets			
Capitalized expenditure for development work	5	113,035	96,253
Patent	6	1,632	1,632
		114,667	**97,885**
Total fixed assets		**114,667**	**97,885**
Current assets			
Short term receivables			
Tax receivables		273	257
Other receivables		412	378
Prepaid expenses and accrued income		2,379	2,643
		3,063	**3,278**
Cash and cash receivables		**15,496**	**22,026**
Total current assets		**18,559**	**25,304**
TOTAL ASSETS		**133,226**	**123,189**
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share capital		23,451	11,712
Fund for development costs		110,972	94,190
		134,422	**105,902**
Accumulated loss			
Share premium		185,043	166,264
Retaind result		-175,090	-141,828
Result for the year		-20,553	-16,480
		-10,600	**7,956**
Total equity		**123,823**	**113,858**
Long term liabilities			
Other long term liabilities	7	800	800
		800	**800**
Current liabilities			
Accounts payable		2,674	2,493
Other current liabilities		3,023	3,413
Accrued expenses and prepaid income		2,906	2,625
		8,604	**8,531**
TOTAL EQUITY AND LIABILITIES		**133,226**	**123,189**

Change in equity

Jan-Dec 2024 12 months KSEK	Share capital	Fund for development costs	Share premium	Accumulated loss incl. result for the year	Total equity
At the beginning of the year	**11,712**	**94,190**	**166,264**	**-158,308**	**113,858**
Rights issue	11,739		28,432		40,171
Transaction costs, rights issue			-9,653		-9,653
Transfer within equity		16,781		-16,781	0
Net result for the year				-20,553	-20,553
At the end of the year	**23,451**	**110,972**	**185,043**	**-195,642**	**123,823**

Jan-Dec 2023 12 months KSEK	Share capital	Fund for development costs	Share premium	Accumulated loss incl. result for the year	Total equity
At the beginning of the year	**8,526**	**74,586**	**144,645**	**-122,224**	**105,533**
Rights issue	3,186	-	23,098	-	26,284
Transaction costs, rights issue	-	-	-1,479	-	-1,479
Transfer within equity	-	19,604	-	-19,604	0
Net result for the year	-	-	-	-16,480	-16,480
At the end of the year	**11,712**	**94,190**	**166,264**	**-158,308**	**113,858**

Cash flow statement

KSEK	Notes	Jan-Dec 2024 12 months	Jan-Dec 2023 12 months
OPERATING ACTIVITIES			
Result after financial items		-20,553	-16,480
Adjustments for items not included in cash flow		-	-
Cash flow from operating activities before change in working capital		**-20,553**	**-16,480**
Cash flow from change in working capital			
Increase (-)/Decrease (+) in operating receivables		215	-1,976
Increase (+)/Decrease (-) in operating liabilities		73	3,243
Cash flow from operating activities		**-20,265**	**-15,213**
Investing activities			
Acquisition of intangible fixed assets	5, 6	-16,781	-19,604
Cash flow from investing activities		**-16,781**	**-19,604**
Financing activities			
Share issue		40,171	26,284
Transaction costs, share issue		-9,653	-1,479
Cash flow from financing activities		**30,517**	**24,805**
Cash flow for the year		**-6,529**	**-10,112**
Cash and cash equivalents at the beginning of the period		**22,026**	**32,038**
Cash and cash equivalents at the end of the period		**15,496**	**22,026**

Notes

Note 1, Accounting principles

All amounts in SEK unless otherwise specified.

General accounting principles
This annual report is prepared in accordance with the Swedish Annual Accounts Act and pursuant to the general recommendations of the Swedish Accounting Standards board BFNAR 2012:1 Annual Accounts and Consolidated Financial Statements (K3).

The accounting principles are unchanged compared to previous years. No new accounting principles that had any significant impact on results or position have been adopted during the year.

Valuation policies, etc.
Assets, provisions and liabilities are measured at cost unless otherwise specified below.

Intangible fixed assets

Research and development costs
Development costs are recognized according to the capitalization model. That means expenditures arising during the development phase are reported as assets when all of the following prerequisites are met:

- It is technically possible to complete the intangible fixed asset for use or sale.
- The intention is to complete the intangible fixed asset and to use it or sell it.
- There are prerequisites for using or selling the intangible fixed asset.
- It is likely that the intangible fixed asset will generate future economic benefits.
- Sufficient and adequate technological, financial and other resources are available to complete the development and use or sell the intangible asset.
- The costs that are attributable to the intangible asset can be calculated reliably.

Other intangible fixed assets
Other intangible assets acquired by the company are recognized at acquisition cost less accumulated amortization and impairment losses.

Amortization
Amortization is recognized on a straight-line basis over the asset's estimated useful life, and as an expense in the income statement. No amortizations have been recorded during the year. Amortization will be recognized when the products are commercialized.

Depreciation of intangible fixed assets
At each balance sheet date, an assessment is made as to whether there is any indication that an asset value is lower than its carrying amount. If such an indication exists, the asset's recoverable amount is calculated.

The recoverable amount is the highest of the fair value less costs to sell and the value in use.

The value in use is calculated as the present value of future cash flows that the asset is expected to generate in the operating activities as well as when it is sold or scrapped. The discount rate applied is before tax and reflects assessments, based on market conditions, of the time value of money and the risks associated with the asset.

An impairment loss recognized in prior periods is only reversed if there has been a change in the estimates used to determine the asset's recoverable amount since the last recognition of impairment loss.

Receivables
Receivables are recognized at the amount that is considered to be collectable based on an individual assessment.

Revenue

Revenue is measured at the fair value of the consideration received or receivable. It is recognized as revenue when it can be reliably calculated, when it is likely that the financial benefits arising from it will be available to the Company, and when the costs incurred or expected to be incurred in respect of the transaction can be measured reliably.

Public grants

Public grants that are not contingent on future performance are recognized as revenue when the conditions for the award of the grant are satisfied. Public grants that are contingent on future performance are recognized as revenue when the performance is delivered. If the grant has been received before the satisfaction of the associated conditions, the grant is recognized as a liability.

A public grant attributable to the acquisition of a fixed asset is recognized as a decrease in the acquisition cost of the asset.

Note 2, Operational leasing - lessee

KSEK	2024	2023
Office rent	119	67
Total	**119**	**67**

The company's lease is valid until 2025-10-31 and can be terminated with a notice period of 6 months. The company's cost for the 2025 non-cancellable lease amounts to 330 thousand SEK.

Note 3, Employees

	2024	2023
Average number of full-time employees	5	5
Total	**5**	**5**

Note 4, This year's tax expense

	2024	2023
Current tax for the year	-	-
Total	**-**	**-**

Total unused deferred tax assets amount to 112,268 KSEK.

Note 5, Capitalized expenditure for development work

KSEK	2024	2023
Accumulated acquisition values		
Beginning of the year	96,253	76,649
Capitalized during the year	16,782	19,604
Capitalized financed by contributions	-	-
Accounted values at end of the year	**113,035**	**96,253**

Acquisition values have been reduced with public contributions from VINNOVA with 240,741 SEK (2013), 206,792 SEK (2014), 75,561 SEK (2015), 10,668 SEK (2016), 307,455 SEK (2017) and 145,497 SEK (2018).

Note 6, Patent

	2024	2023
Accumulated acquisition values		
Beginning of the year	1,632	1,632
Capitalized during the year	-	-
Capitalization financed by contributions	-	-
Accounted values at end of the year	**1,632**	**1,632**

Acquisition values have been reduced with public contributions from Innovationsbron with 80 KSEK (2013) and VINNOVA with 50 KSEK (2015) and 100 KSEK (2019).

Note 7, Other long-term liabilities to credit institutes

	2024	2023
Västra Götalandsregionen	-800	-800
Total	**-800**	**-800**

The loan is conditional and is not subject to an amortization schedule. Obligation to repay the debt arises in conjunction with the exploitation of projects. The creditor may also cancel the debt if the result for which financing has been requested is not achieved.

Note 8, Pledged assets and contingent liabilities

	2024	2023
Pledged assets	None	None
Contingent liabilities	None	None

Note 9, Definitions of key figures

Total balance sheet: Total assets

Solvency: Total equity, including equity part of untaxed reserves, divided with total assets.

Note 10, Significant events after the balance sheet date

- Alzinova participated between January 13-16, 2025 at the J.P. Morgan Healthcare Conference in San Francisco, where management met with a large number of potential partners and investors to present the company's latest positive clinical Alzheimer's data and strong results from the phase 1b study with the vaccine candidate ALZ-101.
- The Company announced that a strategic decision has been made to appoint a CMO on site at the Company's head office in Gothenburg, primarily with the aim of being able to maintain even closer dialogue with the business's R&D team and management team as Alzinova enters the next development phase.
- Alzinova announced that all study participants have completed the final visit in the phase 1 study. All data points will then be processed, analyzed and compiled. The final results for the entire study period are planned to be communicated by the end of March 2025.
- The Company announced that data had been obtained for the treatment arm in which patients were treated with 400 µg in the Company's Phase 1b study. This treatment arm also demonstrated good safety and tolerability.
- A communiqué from the Extraordinary General Meeting stated that a resolution had been passed to adopt an incentive program (LTIP 2025:1) consisting of warrants for members of management, other employees, and key consultants of the Company. In brief, the incentive program entails an issue of up to 4,000,000 warrants. Each warrant entitles the holder to subscribe for one new share in the Company during the period from 15 March 2027 through 31 March 2027, at a subscription price corresponding to 200 percent of the volume-weighted average price of the Company's share during the ten (10) trading days immediately preceding the first offer to acquire warrants, but not less than the quota value of the share.
- Alzinova announced that the final analysis of data from the clinical Phase 1b study with the vaccine candidate ALZ-101, which included patients with early Alzheimer's disease, had been completed. The study's primary and secondary objectives – safety, tolerability, and immunogenicity – were met. Furthermore, the exploratory efficacy measures indicated a stable disease profile with no signs of deterioration. The clinical Phase 1b study conducted by Alzinova was thus concluded.
- On April 2, 2025, the Board of Directors, with the support of authorization, decided to carry out a rights issue of shares, which, if fully subscribed, will provide the Company with approximately SEK 35.7 million before issue costs. Prior to the rights issue, the Company received subscription commitments and issue guarantees corresponding to 85 percent of the rights issue. The main purpose of the Rights Issue is to provide the Company with capital to complete the preparations for the vaccine candidate ALZ-101 for the upcoming clinical study while existing partner dialogues with Big Pharma companies progress.
- The company announced that the incentive program LTIP 2025:1 has been implemented and that Alzinova's board, in accordance with the guidelines decided by the general meeting, has decided to transfer 3,250,000 warrants to the participants.
- Alzinova announced that members of the Company's board and management and other existing shareholders, in addition to previously announced pre-subscribers and underwriters, have submitted declarations of intent to subscribe for the rights issue for a total of approximately SEK 1.0 million.

Signatures

Gothenburg 24 April 2025
Alzinova AB (publ)

Julian Aleksov
Chairman of the board

Anders Blom
Board member

Per-Göran Gillberg
Board member

Clas Malmeström
Board member

Carol Routledge
Board member

Anders Waas
Board member

Tord Labuda
Chief Executive Officer

Our audit report has been submitted
on April 24, 2025

Ernst & Young AB

Linda Sallander
Authorized Auditor

Auditor's report

To the general meeting of the shareholders of Alzinova AB (publ), corporate identity number 556861 – 8168.

Report on the annual accounts

Opinions

We have audited the annual accounts of Alzinova AB (publ) for the financial year 2024. This document contains other information on pages 2 - 24 and 43 – 44. The company's annual accounts can be found on the pages 25 – 39 in this document.

In our opinion, the annual accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of Alzinova AB (publ) as of 31 December 2024 and its financial performance and cash flow for the year. The statutory administration report is consistent with the other parts of the annual accounts.

We therefore recommend that the general meeting of shareholders adopts the income statement and balance sheet.

Basis for Opinions

We conducted our audit in accordance with International Standards on Auditing (ISA) and generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent of Alzinova AB (publ) in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

Information other than the annual accounts

It is the Board of Directors and the CEO who are responsible for the other information. The other information can be found on the pages 2 – 24 and 43 - 44 but does not include the annual accounts and our auditor's accounts regarding it.

Our statement regarding the Annual Accounts does not include this information and we do not make a statement confirming this other information.

In connection with our audit of the Annual Accounts, it is our responsibility to read the information identified above and consider whether the information is materially inconsistent with the Annual Accounts. In this review, we also take into account the knowledge we have otherwise acquired during the audit and assess whether the information otherwise appears to contain material misstatements.

If, based on the work that has been done regarding this information, we conclude that the other information contains a material misstatement, we are obliged to report this. We have nothing to report in that regard.

Responsibilities of the Board of Directors and the Managing Director

The Board of Directors and the Managing Director are responsible for the preparation of the annual accounts and that they give a fair presentation in accordance with the Annual Accounts Act. The Board of Directors and the Managing Director are also responsible for such internal control as they determine is necessary to enable the preparation of annual accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts, The Board of Directors and the Managing Director are responsible for the assessment of the company's ability to continue as a going concern. They disclose, as applicable, matters related to going concern and using the going concern basis of accounting.

Auditor's responsibility
Our objectives are to obtain reasonable assurance about whether the annual accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinions. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of the company's internal control relevant to our audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors and the Managing Director.

- Conclude on the appropriateness of the Board of Directors' and the Managing Director's use of the going concern basis of accounting in preparing the annual accounts. We also draw a conclusion, based on the audit evidence obtained, as to whether any material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual accounts or, if such disclosures are inadequate, to modify our opinion about the annual accounts. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the annual accounts, including the disclosures, and whether the annual accounts represent the underlying transactions and events in a manner that achieves fair presentation.

We must inform the Board of Directors of, among other matters, the planned scope and timing of the audit. We must also inform of significant audit findings during our audit, including any significant deficiencies in internal control that we identified.

Report on other legal and regulatory requirements

Opinions
In addition to our audit of the annual accounts, we have also audited the administration of the Board of Directors and the Managing Director of Alzinova AB (publ) for the financial year 2024 the proposed appropriations of the company's profit or loss.

We recommend to the general meeting of shareholders that the profit be appropriated in accordance with the proposal in the statutory administration report and that the members of the Board of Directors and the Managing Director be discharged from liability for the financial year.

Basis for Opinions
We conducted the audit in accordance with generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent of Alzinova AB (publ) in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

Responsibilities of the Board of Directors and the Managing Director
The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is justifiable considering the requirements which the company's type of operations, size and risks place on the size of the company's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the administration of the company's affairs. This includes among other things continuous assessment of the company's financial situation and ensuring that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner. The Managing Director shall manage the ongoing administration according to the Board of Directors' guidelines and instructions and among other matters take measures that are necessary to fulfill the company's accounting in accordance with law and handle the management of assets in a reassuring manner.

Auditor's responsibility
Our objective concerning the audit of the administration, and thereby our opinion about discharge from liability, is to obtain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of Directors or the Managing Director in any material respect:

- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

Our objective concerning the audit of the proposed appropriations of the company's profit or loss, and thereby our opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always detect actions or omissions that can give rise to liability to the company, or that the proposed appropriations of the company's profit or loss are not in accordance with the Companies Act.

As part of an audit in accordance with generally accepted auditing standards in Sweden, we exercise professional judgment and maintain professional scepticism throughout the audit. The examination of the administration and the proposed appropriations of the company's profit or loss is based primarily on the audit of the accounts. Additional audit procedures performed are based on our professional judgment with starting point in risk and materiality. This means that we focus the examination on such actions, areas and relationships that are material for the operations and where deviations and violations would have particular importance for the company's situation. We examine and test decisions undertaken, support for decisions, actions taken and other circumstances that are relevant to our opinion concerning discharge from liability. As a basis for our opinion on the Board of Directors' proposed appropriations of the company's profit or loss we examined whether the proposal is in accordance with the Companies Act.

Gothenburg on April 24, 2025
Ernst & Young AB

Linda Sallander
Authorized Public Accountant

Glossary and abbreviations

Begrepp	Definition
Aβ42 - amyloid-beta 42	A naturally occurring peptide (part of a protein) that aggregates in the brain and causes Alzheimer's disease.
"First-in-Class"	A product considered superior to other competitors in its category; can be compared to "first-in-class," which refers to being first to market with a product.
Biological therapies	Treatments that are derived from living organisms, such as proteins.
Biomarker	A measurable indicator of a disease state.
EMA	The European Medicines Agency.
FDA	The U.S. Food and Drug Administration.
Fibrils	Abeta fibrils are stable protein aggregates of amyloid beta peptides that form amyloid plaques in the brain.
R&D	Abbreviation for research and development.
IP	Intellectual property, e.g., patents.
Monoclonal antibody	A type of antibody produced in the laboratory from a single clone of immune cells and directed against a specific protein.
Oligomers	Aggregated proteins or peptides, here referring to soluble peptide aggregates.
Plaques	Localized accumulation of aggregated, insoluble protein—primarily composed of the Aβ42 peptide in Alzheimer's disease.
Disease-modifying treatment	A treatment that targets the underlying cause of the disease.
Tolerability	The degree of side effects from a drug that can be tolerated by a patient.

Financial calendar

Event	Date
Interim report 1, 2025	15 May 2025
Annual Gerneral Meeting 2025	28 May 2025
Half-year report, 2025	21 August 2025
Interim report 3, 2025	13 November 2025
Year-end report, 2025	26 February 2026

Financial reports are available on the Company´s website www.alzinova.com from the day they are made public.

For further information, please contact:

Tord Labuda, CEO
tord.labuda@alzinova.com,

Erik Kullgren, CFO
erik.kullgren@alzinova.com,

or send an e-mail directly to
info@alzinova.com

Alzinova AB (publ)

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease, which focuses on targeting toxic amyloid-beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide™ technology makes it possible to develop disease-modifying treatments that accurately target the toxic amyloid-beta oligomers that are central to the onset and progression of the disease. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases. It is estimated that more than 30 million people in the world today have Alzheimer's disease and the number is expected to triple by 2050. Based on the same technology, the Company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The Company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com

Alzinova AB
Visiting address: Entreprenörsstråket 10, 431 53, Mölndal
Postal address: Gemenskapens gata 9, 431 53, Mölndal

alzinova